9月15日，赛默飞世尔盘中上涨3.08%，报632.99美元/股，成交额8835.87万美元。
消息面上，近期多家投行密集上调赛默飞世尔评级及目标价。其中瑞银将其评级从中性大幅上调至买入，目标价由540美元跃升至730美元，为近期最激进的看多信号；Baird将目标价上调至686美元并维持跑赢大盘评级；汇丰将目标价上调至690美元。此外，知名机构Citrini近日更新医疗板块"卖铲人"投资组合，赛默飞世尔被纳入其中，该机构认为AI在药物研发中的加速应用及生物技术融资回暖将持续利好生命科学工具供应商。此前公司二季度业绩大超预期，调整后每股收益6.03美元超预期5.71美元，营收上调至474亿至481亿美元，基本面改善为投行集体看多提供了支撑。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.